SENS$7.76
$7.74
Chart
Performance
Key Stats
AI SENS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldSenseonics Holdings, Inc. shows potential in its niche but faces significant financial challenges and a highly competitive market. Fundamentally it is weak, technically neutral, and thematically moderate. Best suited for speculative investors with a high tolerance for risk.
Thematic
The growing diabetes market and continuous glucose monitoring (CGM) technology present a positive long-term theme, but Senseonics faces strong competition and adoption hurdles.
Fundamental
The company is not currently profitable, generates negative free cash flow, and has a negative equity position. While revenue is growing, it is not yet translating to sustainable profitability.
Technical
The stock shows mixed signals. While long-term trends suggest some underlying support, recent performance indicates downward pressure and potential for further decline in the short term.
| Factor | Score |
|---|---|
| Diabetes Market Growth | 75 |
| CGM Technology Adoption | 70 |
| Competitive Landscape | 40 |
| Regulatory & Reimbursement Environment | 50 |
| Product Differentiation | 60 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 50 |
| Balance Sheet Health | 5 |
| Cash Flow | 15 |
| Debt Level | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 50 |
| Momentum | 60 |
| Volume | 40 |
| Support & Resistance | 70 |
| Recent Performance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Performance
The stock has shown positive performance over the last month (+12.33%) and year-to-date (+17.32%), indicating recent investor interest and positive momentum.
Low Beta
A Beta of 0.94 suggests the stock is slightly less volatile than the overall market, which can be appealing for risk-averse investors.
Bearish Points (8)
Recent Price Decline
The stock has experienced a recent price drop of -3.48% with a significant short-term decline over the last 5 days (-4.33%), indicating potential selling pressure.
Small Employee Base
With only 117 employees, the company's operational scale might be limited, potentially impacting its ability to scale production or expand market reach efficiently.
Calendar
August 2025
7
Next Earnings Date
H: $-0.02
A: $-0.02
L: $-0.02
H: 6.42M
A: 6.02M
L: 5.30M
Profile
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Seasonals
Price Target
1.55 USD
The 39 analysts offering 1 year price forecasts for SENS have a max estimate of 2.00 and a min estimate of 1.25.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Leading direct competitor in the continuous glucose monitoring (CGM) market, offering rival CGM systems.
Weight: 97
Major direct competitor in the continuous glucose monitoring (CGM) market with its FreeStyle Libre system.
Weight: 95
Developer of insulin pumps that often integrate with CGM systems, part of the broader automated insulin delivery ecosystem.
Weight: 94
Manufacturer of the Omnipod tubeless insulin pump system, which frequently integrates with CGM technologies.